Royalty Pharma Lifts Elan Bid to $13.00 a Share Plus CVR

Royalty Pharma raised its offer for Elan Corp Plc (ELN) to $13.00 a share plus a contingent value right of as much as $2.50 a share, the company said today.

The offer, previously at $12.50 per share, potentially values each Elan share at up to $15.50 if additional CVR payment events occur, according to the statement.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Jacqueline Simmons at jackiem@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.